418 related articles for article (PubMed ID: 21600850)
1. Rationale for pertussis booster vaccination throughout life in Europe.
Zepp F; Heininger U; Mertsola J; Bernatowska E; Guiso N; Roord J; Tozzi AE; Van Damme P
Lancet Infect Dis; 2011 Jul; 11(7):557-70. PubMed ID: 21600850
[TBL] [Abstract][Full Text] [Related]
2. Pertussis immunisation in adolescents and adults--Bordetella pertussis epidemiology should guide vaccination recommendations.
Heininger U; Cherry JD
Expert Opin Biol Ther; 2006 Jul; 6(7):685-97. PubMed ID: 16805708
[TBL] [Abstract][Full Text] [Related]
3. Epidemiological and immunological reasons for pertussis vaccination in adolescents and adults.
Nitsch-Osuch A; Korzeniewski K; Kuchar E; Zielonka T; Życińska K; Wardyn K
Respir Physiol Neurobiol; 2013 Jun; 187(1):99-103. PubMed ID: 23419520
[TBL] [Abstract][Full Text] [Related]
4. Using computer simulations to compare pertussis vaccination strategies in Australia.
Hethcote HW; Horby P; McIntyre P
Vaccine; 2004 Jun; 22(17-18):2181-91. PubMed ID: 15149775
[TBL] [Abstract][Full Text] [Related]
5. Re-emergence of pertussis: what are the solutions?
Libster R; Edwards KM
Expert Rev Vaccines; 2012 Nov; 11(11):1331-46. PubMed ID: 23249233
[TBL] [Abstract][Full Text] [Related]
6. Immunization against pertussis in adolescents and adults.
Esposito S; Principi N;
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S89-S95. PubMed ID: 27130670
[TBL] [Abstract][Full Text] [Related]
7. [Global pertussis epidemiology and immunization strategies].
Zhang WH
Zhongguo Yi Miao He Mian Yi; 2009 Oct; 15(5):467-72. PubMed ID: 20084979
[TBL] [Abstract][Full Text] [Related]
8. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria.
Rendi-Wagner P; Paulke-Korinek M; Stanek G; Khanakah G; Kollaritsch H
Pediatr Infect Dis J; 2007 Sep; 26(9):806-10. PubMed ID: 17721375
[TBL] [Abstract][Full Text] [Related]
9. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
[TBL] [Abstract][Full Text] [Related]
10. [Whooping cough is a risk to infants. The disease is circulating among adolescents and adults].
Nilsson L; Von Segebaden K; Blennow M; Linde A; Uhnoo I
Lakartidningen; 2013 Sep 11-17; 110(37):1599-602. PubMed ID: 24163932
[No Abstract] [Full Text] [Related]
11. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence?
Godfroid F; Denoël P; Poolman J
Expert Rev Vaccines; 2005 Oct; 4(5):757-78. PubMed ID: 16221076
[TBL] [Abstract][Full Text] [Related]
12. Is adolescent pertussis vaccination preferable to natural booster infections?
Hallander HO; Nilsson L; Gustafsson L
Expert Rev Clin Pharmacol; 2011 Nov; 4(6):705-11. PubMed ID: 22111856
[TBL] [Abstract][Full Text] [Related]
13. Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants?
van der Maas NA; Mooi FR; de Greeff SC; Berbers GA; Spaendonck MA; de Melker HE
Vaccine; 2013 Sep; 31(41):4541-7. PubMed ID: 23933365
[TBL] [Abstract][Full Text] [Related]
14. [Old problems and new strategies in the fight against pertussis].
Carlino C; Zaratti L; Franco E
Ig Sanita Pubbl; 2013; 69(4):473-80. PubMed ID: 24091847
[TBL] [Abstract][Full Text] [Related]
15. [Pertussis in the Netherlands].
de Greeff SC; de Melker HE; Mooi FR
Ned Tijdschr Geneeskd; 2010; 154():A1383. PubMed ID: 20170575
[TBL] [Abstract][Full Text] [Related]
16. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.
Bechini A; Tiscione E; Boccalini S; Levi M; Bonanni P
Vaccine; 2012 Jul; 30(35):5179-90. PubMed ID: 22709953
[TBL] [Abstract][Full Text] [Related]
17. Bordetella pertussis strain variation and evolution postvaccination.
Kallonen T; He Q
Expert Rev Vaccines; 2009 Jul; 8(7):863-75. PubMed ID: 19538113
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.
Purdy KW; Hay JW; Botteman MF; Ward JI
Clin Infect Dis; 2004 Jul; 39(1):20-8. PubMed ID: 15206048
[TBL] [Abstract][Full Text] [Related]
19. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
[TBL] [Abstract][Full Text] [Related]
20. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection.
Barkoff AM; Gröndahl-Yli-Hannuksela K; Vuononvirta J; Mertsola J; Kallonen T; He Q
Vaccine; 2012 Nov; 30(48):6897-902. PubMed ID: 22981763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
